Skip to main content
CAMBIUM BIO LIMITED logo

CAMBIUM BIO LIMITED — Investor Relations & Filings

Ticker · CMB ISIN · AU0000327769 ASX Professional, scientific and technical activities
Open in API
Filings indexed 504 across all filing types
Latest filing 2013-11-24 Regulatory Filings
Country AU Australia
Listing ASX CMB

About CAMBIUM BIO LIMITED

https://www.cambium.bio

Cambium Bio Limited is a clinical-stage regenerative medicine company focused on developing innovative cellular therapies to treat unmet medical needs in ophthalmology and inflammatory diseases. The company's primary focus is on its lead candidate, EluRegen, a first-in-class topical biologic designed for the treatment of corneal epithelial defects and dry eye disease. Utilizing its proprietary technology platforms, the company aims to harness the regenerative potential of biologics to provide effective treatments for chronic conditions. In addition to its ophthalmic pipeline, the company maintains assets in the field of mesenchymal stem cell therapies, including Progenza, which targets osteoarthritis and neuropathic pain. The company emphasizes a data-driven approach to clinical development, seeking to improve patient outcomes through advanced tissue engineering and cell-based solutions.

Recent filings

Filing Released Lang Actions
Regeneus to fast-track human cells under new Japanese laws 2 pages 193.9KB
Regulatory Filings Classification · 90% confidence The document is a press release announcing new regulatory opportunities in Japan for Regeneus to fast-track human cell therapies under new laws. It discusses the company's plans and the regulatory environment but does not contain financial statements, detailed financial performance, or regulatory filings. It is a corporate announcement about business strategy and regulatory environment rather than a financial report or regulatory filing. The document length is 3564 characters, which is relatively short and typical for a press release. Therefore, the best fitting category is a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories like Annual Report, Earnings Release, or Capital Update.
2013-11-24 English
Presentation at BBY Life Sciences Conference Covering Letter 2 pages 184.4KB
Investor Presentation Classification · 90% confidence The document is an ASX announcement about a presentation delivered by John Martin of Regeneus Ltd at the BBY Life Sciences Conference in November 2013. It explicitly states it is a presentation and provides background information about the company. The document length is short (1635 characters) and does not contain financial statements or detailed financial analysis. It is essentially a notice or summary of a presentation event rather than the presentation slides themselves or a detailed investor presentation document. Therefore, the best fitting category is Investor Presentation (IP), as it relates to a presentation for investors focusing on company information and strategy.
2013-11-18 English
Presentation at BBY Life Sciences Conference - November 2013 18 pages 879.6KB
Investor Presentation Classification · 100% confidence The document is a detailed presentation from a life sciences conference by Regeneus (ASX:RGS) dated November 2013. It includes extensive information about the company's business model, product pipeline, technology platforms, market strategy, clinical data, and outlook for the next 12 months. The content is structured as a slide presentation with forward-looking statements, product descriptions, competitive advantages, and strategic plans. There are no financial statements, audit opinions, or regulatory filings included. The document is clearly intended for investors or stakeholders to provide an overview of the company's operations and future prospects. This matches the definition of an Investor Presentation (IP). The document length is substantial (over 14,000 characters), and it is not merely an announcement or a brief summary, so it is not an RPA or FS. Therefore, the appropriate classification is Investor Presentation (IP).
2013-11-18 English
Press Release re Novel canine cancer vaccine 2 pages 200.7KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Regeneus has received approval from the US Department of Agriculture to commercialize a novel canine cancer vaccine in the USA. It discusses the vaccine's development, pre-clinical testing, and plans for a marketing study. There are no financial statements, regulatory filings, or detailed financial data presented. The document is a corporate announcement about a product commercialization milestone rather than a financial report, regulatory filing, or management discussion. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a press release about a business development, which is best classified under Regulatory Filings (RNS) as a general corporate announcement that does not fit other specific categories.
2013-11-13 English
HiQCell stem cell therapy now available in Melbourne 2 pages 201.4KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the availability of HiQCell stem cell therapy in Melbourne. It provides information about the treatment, the involved medical specialists, and the facilities but does not contain any financial data, regulatory filings, or corporate governance information. There is no indication of financial results, shareholder votes, management changes, or capital structure updates. The content is promotional and informational about a product launch and service availability. Therefore, it does not fit into any of the specific financial or regulatory filing categories. The best fit is Regulatory Filings (RNS) as a general announcement that does not fall into other categories.
2013-10-29 English
Annual Report to shareholders 68 pages 1.9MB
Annual Report Classification · 100% confidence The document is titled '2013 Annual Report' and contains detailed sections typical of an annual report, including a message from the Executive Chairman and CEO, corporate directory, directors' report, auditor's independence declaration, corporate governance statement, consolidated financial statements, notes to the financial statements, directors' declaration, and independent auditor's report. The content covers the full financial year ended 30 June 2013, with comprehensive financial and business highlights, strategic outlook, and detailed corporate governance information. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement or summary. Therefore, this document fits the definition of an Annual Report (10-K). FY 2013
2013-10-28 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.